ADVANCES IN THE KNOWLEDGE AND
TREATMENT OF DYSLIPOPROTEINEMIAS
Fausto Garmendia*
SUMMARY
A review of the lipidic and non-lipidic cardiovascular risk factors is done. The
increase of LDL, VLDL, IDL cholesterol, non-HDL triglycerides and lipoprotein(a) as well
as HDL cholesterol decrease were considered as main lipidic cardiovascular risk factors.
Dyslipoproteinemias are classified as primary and secondary. Primary dyslipoproteinemias
are inborn errors of lipid metabolism, familiar or non-familiar, including common
hypercholesterolemia, combined familiar hyperlipidemia, familiar hypercholesterolemia,
familiar hypertrigliceridemia, VLDL remanents hyperlipidemia and primary quilomicronemia.
The secondary dyslipoproteinemias are produced by various diseases, including
hypotiroidism, diabetes mellitus, nephrotic syndrome, chronic biliary obstruction, renal
insufficiency and so on; there are some drugs that modify lipid metabolism such as
alcohol, beta-blockers, diuretics, progestagens, corticosteroides, and many others. It is
emphasized that the fasting lipid profile alone is not sufficient to determine the lipidic
metabolic disorder, and it is suggested the convenience of conducting postprandial
studies. In the therapeutic handling it is necessary to consider the diet and physical
exercises; and when these measures are not sufficient, try to normalize the lipid profile
by using drugs such as hydroxi-metil-glutaryl coenzime A inhibitors and fibric acids
derivatives. Therapeutic interventions, supported by results of multicentric international
mega-studies, have shown a decrease in the prevalence of the cardiovascular events and the
related morbidity and mortality.
Key words: Lipids; cholesterol; lipoproteins, HDL cholesterol;
lipoproteins, LDL cholesterol; lipoproteins, VLDL cholesterol.
Texto
completo del artículo |
|